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Autoimmunity, Immunoglobulin
Adsorption and Dilated
Cardiomyopathy: Has the Time
Come for Randomized Clinical
Trials?*
Douglas L. Mann, MD, FACC
Houston, Texas
Over the past 10 to 15 years there has been increasing
evidence suggesting that abnormalities in cellular and hu-
moral immunity may contribute to the overall pathogenesis
of dilated cardiomyopathy. Circulating autoantibodies to a
variety of cardiac antigens including G-protein–linked re-
ceptors (such as those to beta1-adrenoreceptors and musca-
rinic receptors), mitochondrial antigens, adenosine diphos-
phate, adenosine triphosphate carrier proteins and cardiac
myosin heavy chain have been identified in patients with
dilated cardiomyopathy (1–4). Immunization with certain
cardiac muscle antigens such as alpha-myosin heavy chain
can result in the development of a dilated cardiac phenotype
in certain susceptible strains of mice (5). Moreover, it has
been possible to demonstrate either cardiodepressant (6,7)
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or cardiostimulatory effects (8) for some circulating autoan-
tibodies. Nonetheless, a precise interpretation of the above
findings has been complicated by the knowledge that low
titers of autoantibodies, which can be part of the normal
immunlogic repertoire, are not always pathogenetic. For
example, tissue injury secondary to ischemia or infection
may lead to autoantibody production because of alterations
of self-antigens or exposure of antigens that are normally
sequestered from the immune system. In such situations, the
generation of autoantibodies is the result, and not the cause,
of the tissue injury. Furthermore, observations about auto-
immune responses are generally made in patients with
established disease; accordingly, any inferences regarding
cause and effect are, invariably, indirect and circumstantial.
If cardiac autoantibodies do play a role in either the
initiation or progression of dilated cardiomyopathy, then it
follows that their removal would be expected to lead to
disease stabilization or improvement. Conversely, if cardiac
autoantibodies are simply markers of the underlying auto-
immune process, then efforts to remove them would not
lead to an improvement in clinical outcomes. With these
considerations in mind, the report by Schimke et al. (9) in
this issue of the Journal is of particular interest. Schimke et
al. (9) present data suggesting that immunoadsorption
results in a significant lowering of a portfolio of plasma
markers indicative of oxidative stress, including thiobarbi-
turic acid-reactive substances (TBARS), anti-oxidized low-
density lipoprotein autoantibodies and lipid peroxides
(LPO) in patients with dilated cardiomyopathy. Moreover,
the changes in TBARS levels correlated with changes in
New York Heart Association (NYHA) functional class (r 5
0.34, p 5 0.08), whereas the changes in LPO levels were
inversely correlated with changes in left ventricular ejection
fraction (r 5 20.33; p 5 0.08). Although this interesting
study must be viewed as provisional because of the small
numbers of patients, this study raises the broader question
of whether it is time to consider performing randomized
clinical trials with immunoadsorption in patients with
dilated cardiomyopathy. Before addressing this issue, how-
ever, it is first appropriate to review what is known clinically
about immunoadsorption in dilated cardiomyopathy.
Immunoadsorption and dilated cardiomyopathy. The
technique of immunoadsorption, which first gained popu-
larity for treating patients with familial heterozygous hyper-
cholesterolemia (10), has also been used to treat patients
with a variety of autoimmune diseases, including myasthe-
nia gravis, systemic lupus erythematosis, Guillain-Barre´
syndrome and Sjo¨rgren syndrome. Removal of autoantibod-
ies with immunoadsorption is achieved by passing a pa-
tient’s plasma over columns that contain immobilized anti-
bodies against immunoglobulin (IgG) kappa and lambda
light chains and IgG heavy chains. To prevent infectious
complications that might arise from inappropriate lowering
of circulating IgG levels, intravenous (IV) IgG is often given
back at the end of a period of treatment (IgG replacement
therapy). Immunoadsorption depletes a variety of circulat-
ing immunoglobulins, including autoantibodies, alloanti-
bodies (i.e., antibodies directed against antigens from a
genetically distinct member of the same species) and circu-
lating immune complexes.
Immunoadsorption for patients with dilated cardiomyop-
athy was first reported in an uncontrolled pilot study by
Wallukat et al. (11), who showed that this technique
efficiently removed circulating antibodies directed against
the beta1-adrenoreceptor. They also observed an improve-
ment in NYHA functional class in patients (n 5 8) with
dilated cardiomyopathy. This study was soon followed by
another pilot study that reported an improvement in short-
term hemodynamic effects in nine patients with severe
(NYHA functional class III and class IV) heart failure, who
were refractory to conventional medical therapy
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(angiotensin-converting enzyme [ACE] inhibitors, digi-
talis, diuretics and IV beta-blockers) (12). In this study,
Dorffel et al. showed that immunoadsorption resulted in a
significant improvement in cardiac output and a significant
decrease in left ventricular filling pressure and systemic
vascular resistance (12). However, these early studies lacked
a concurrent control group. Recently, the hemodynamic
effects of immunoadsorption have been reported (13) in 18
patients with dilated cardiomyopathy who were randomized
for three months to immunoadsorption and subsequent IgG
replacement or conventional therapy (ACE inhibitors, dig-
italis, diuretics). Felix et al. (13) showed that immunoad-
sorption and IV IgG administration resulted in a significant
improvement in cardiac index and stroke volume index, as
well as a decrease in systemic vascular resistance, whereas no
significant change occurred in these parameters in the
control group.
Most recently, Mu¨ller et al. (14) studied 34 patients with
idiopathic dilated cardiomyopathy (NYHA functional class
II or worse) who had high circulating titers of autoantibod-
ies directed against the beta1-adrenoreceptors. All patients
were receiving standard heart failure therapy, including
ACE inhibitors, digitalis, diuretics and oral beta-blockers.
In this case-control study, the first 17 patients received
standard therapy, whereas the next 17 patients received
immunoadsorption (without IgG replacement therapy) for
five consecutive days; patients were then followed serially for
one year. The investigators reported that immunoadsorp-
tion therapy resulted in a significant lowering of anti-beta1-
adrenoreceptor antibodies in the treatment group, whereas
the anti-beta1-adrenoreceptor antibody titer remained un-
changed in the control group. Within one year of treatment,
there was a significant (’70%) increase in ejection fraction
and a significant (’15%) decrease in left ventricular end-
diastolic dimension in the treatment group, whereas no
significant changes occurred in these parameters in the
untreated patients (14). Thus, taken together, the above
studies suggest that immunoadsorption leads to improve-
ments not only in left ventricular structure and function but
also in functional status in selected patients with dilated
cardiomyopathy.
Is there sufficient evidence to support the initiation of
randomized clinical trials with immunoadsorption therapy for
patients with dilated cardiomyopathy? Before addressing this
question, it is perhaps important to identify the existing
gaps in our knowledge with respect to immunoadsorption in
patients with dilated cardiomyopathy. First, and perhaps
foremost, it will be important to identify the subsets of
patients with dilated cardiomyopathy that will benefit the
most from immunoadsorption therapy. In this regard, the
extant literature does not delineate whether all patients with
dilated cardiomyopathy will benefit from immunoadsorp-
tion therapy, or whether patients with elevated levels of
circulating autoantibodies (e.g., anti-beta1-adrenoreceptor
antibodies) should be studied. It should also be emphasized
that immunoadsorption can be quite expensive (’$30,600/
patient/year [14]). Thus, this technique should not be used
indiscriminately. Presumably, patients with high auto-
antibody titers would benefit the most. However, it is also
reasonable to ask whether myocardial biopsies should also
be used to look for markers of immune activation in select
patients.
Second, the mechanism(s) of action of immunoadsorp-
tion is not known. Although studies have demonstrated
decreases in circulating autoantibodies, it is not at all clear
that a cause-and-effect relationship has been established.
Furthermore, immunoadsorption can lead to a decline in
systemic vascular resistance independent of the removal of
circulating auto-antibodies (15). Thus, part of the hemody-
namic benefit that has been observed may be nonspecific. In
this issue of the Journal, Schimke et al. (9) present data from
a substudy from the previous report by Mu¨ller et al. (14).
These investigators raise the interesting possibility that
alterations in oxidative stress levels may have been respon-
sible for the salutary effects observed following immunoad-
sorption (9). Although the study by Schminke et al. (9) is
carefully done, the number of patients in each group (n 5 9)
is too small to draw meaningful conclusions. Moreover, the
correlations between the changes in levels of oxidative stress
and improvements in clinical outcomes are modest. Thus,
these interesting studies should be viewed as provisional
and/or hypothesis-generating.
A third gap in terms of our understanding of immuno-
adsorption therapy for dilated cardiomyopathy is that the
optimal strategy for immunoadsorption has yet to be deter-
mined. Different investigators use different protocols and
different immunoadsorbent devices. Moreover, the use of
IgG replacement in some of the immunoadsorption proto-
cols may in and of itself lead to improvements in clinical
status for patients with dilated cardiomyopathy, as has
recently been shown by Gullestad et al. (16). Thus, it will be
imperative to optimize immunoadsorption protocols for
patients with dilated cardiomyopathy.
Finally, it is not clear from existing studies whether
immuoadsorption alone, which would be expected to mod-
ulate humoral immunity, will be sufficient in the long term,
or whether it may be necessary to incorporate strategies that
lead to suppression of cellular-mediated immunity as well.
Nonetheless, despite the gaps in our knowledge base that
are detailed above, the existing studies, as well as the recent
report by Schimke et al. (9) in this issue of the Journal,
suggest that immunoadsorption therapy for dilated cardio-
myopathy has progressed well beyond phenomenology and
has matured to the extent where randomized clinical trials
would appear to be warranted for selected groups of pa-
tients. In this regard, one might envision three treatment
arms: conventional therapy, conventional therapy plus im-
munoadsorption and conventional therapy plus immunoad-
sorption plus IV IgG replacement. Ideally these studies
would be conducted in a blinded manner (no easy task) and
would be performed, at least initially, in selected patients
chosen on the basis of high circulating titers of auto-
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antibodies and/or findings consistent with immune activa-
tion on myocardial biopsy. Although the cost of such a study
will likely be substantial, if properly done, the results of such
a study would almost certainly be priceless in terms of the
new insights that it would provide into the pathogenesis of
dilated cardiomyopathy.
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